Scynexis (SCYX) Share-based Compensation (2013 - 2026)
Scynexis (SCYX) posted Share-based Compensation of $580000.0 for Q1 2026, down 15.57% on a QoQ basis from $687000.0 in Q4 2025, and down 29.18% year-over-year from $819000.0 in Q1 2025.
Scynexis (SCYX) Share-based Compensation (2013 - 2026) Analysis & Trends
Scynexis' Share-based Compensation history runs 14 years deep, the most recent figure standing at $580000.0 for Q1 2026.
- Quarterly Share-based Compensation fell 29.18% year-over-year to $580000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.6 million (down 25.21% YoY) and the FY2025 annual result came in at $2.9 million, down 14.76% from the prior year.
- Share-based Compensation was $580000.0 for Q1 2026 at Scynexis, down from $687000.0 in the prior quarter.
- Across five years, Share-based Compensation topped out at $1.1 million in Q2 2022 and bottomed at $454000.0 in Q4 2022.
- A 5-year average of $752882.4 and a median of $705000.0 in 2024 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2022 — Share-based Compensation soared 125.0% — and 2025, when it tumbled 44.44%.
- Scynexis' Share-based Compensation stood at $454000.0 in 2022, then rose by 22.69% to $557000.0 in 2023, then surged by 76.12% to $981000.0 in 2024, then fell by 29.97% to $687000.0 in 2025, then fell by 15.57% to $580000.0 in 2026.
- Business Quant data shows SCYX's Share-based Compensation at $580000.0 in Q1 2026, $687000.0 in Q4 2025, and $500000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 43.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 25.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 125.69 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 58.30 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 56.50 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 55.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 21.00 Mn |
| 10 | Scynexis | 21.55 Mn | -15.20 Mn | - | 580,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 580,000.00 |
| Mar 31, 2026 | 580,000.00 |
| Dec 31, 2025 | 687,000.00 |
| Dec 31, 2025 | 687,000.00 |
| Sep 30, 2025 | 500,000.00 |
| Sep 30, 2025 | 500,000.00 |
| Jun 30, 2025 | 820,000.00 |
| Jun 30, 2025 | 820,000.00 |
| Mar 31, 2025 | 819,000.00 |
| Mar 31, 2025 | 819,000.00 |
| Dec 31, 2024 | 981,000.00 |
| Dec 31, 2024 | 981,000.00 |
| Sep 30, 2024 | 900,000.00 |
| Sep 30, 2024 | 900,000.00 |
| Jun 30, 2024 | 759,000.00 |
| Jun 30, 2024 | 759,000.00 |
| Mar 31, 2024 | 705,000.00 |
| Mar 31, 2024 | 705,000.00 |
| Dec 31, 2023 | 557,000.00 |
| Dec 31, 2023 | 557,000.00 |